Journal
TRENDS IN CANCER
Volume 4, Issue 6, Pages 418-428Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2018.04.001
Keywords
-
Categories
Funding
- National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR001880]
- Parker Institute for Cancer Immunotherapy
- Basser Center for BRCA at Penn
- NIH [R01 CA1691213]
Ask authors/readers for more resources
Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer. In this Review article, we discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of prevention vaccines for this and other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available